4suxxess welcomes you!



Setup. Growth. Restructuring. Turnaround.

 

At 4suxxess, we offer you a team of business architects dedicated to support your company with services designed to enable you to enhance your competitiveness - whether it’s overcoming barriers to success or developing markets locally and globally.

4suxxess provides experienced executive professionals, with the right skill sets to ensure success in challenging assignments and projects.


PharmaTimes: News RSS

GSK/Innoviva’s Trelegy Ellipta wins expanded nod for COPD (Wed, 25 Apr 2018)
US regulators have approved GlaxoSmithKline and Innoviva’s Trelegy Ellipta to treat a wider population of chronic obstructive pulmonary disease (COPD) patients.
>> Read More

Shire, Takeda move closer to merger deal (Wed, 25 Apr 2018)
Shire’s Board has notified Takeda that it would be “willing to recommend" the latter’s latest merger proposal to shareholders, which is now valued at £46 billion pounds.
>> Read More

Pfizer’s Mylotarg wins EU approval for AML (Wed, 25 Apr 2018)
European regulators have cleared Pfizer’s Mylotarg to treat a certain subset of patients with acute myeloid leukaemia (AML).
>> Read More

FDA advisors back Lilly/Incyte’s rheumatoid arthritis drug (Tue, 24 Apr 2018)
US regulatory advisors are backing approval of the lower dose form of Eli Lilly and Incyte’s once-daily JAK inhibitor baricitinib as treatment for rheumatoid arthritis (RA).
>> Read More

MHRA bans valproate without pregnancy prevention programme (Tue, 24 Apr 2018)
The Medicines and Healthcare products Regulatory Agency (MHRA) has changed the licence for valproate medicines, so that they can no longer be prescribed to females of child-bearing age unless they are on the pregnancy prevention programme.
>> Read More